US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

49.19

-0.2900-0.59%

Post-market: 49.190.00000.00%19:30 EDT

Volume:322.54K

Turnover:15.89M

Market Cap:15.04B

PE:22.06

High:49.58

Open:49.49

Low:49.03

Close:49.48

52wk High:55.49

52wk Low:45.77

Shares:305.78M

Float Shares:305.78M

Volume Ratio:0.65

T/O Rate:0.11%

Dividend:2.11

Dividend Rate:4.29%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.61

PE(LYR):19.95

Loading ...

Overview Company News Filings

Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

EMA Partners Appoints Alicia Yi as Group Executive Advisor, Strengthening Executive Search & Leadership Advisory Capabilities Across APAC

Press Release: Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

Press Release: LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Emera price target raised to C$74 from C$73 at CIBC

Press Release: GENFIT Annual Combined General Meeting of June 15, 2026 -- Availability of Preparatory Documents

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

Analysts Have Conflicting Sentiments on These Utilities Companies: Emera (EMA), PPL (PPL) and Algonquin Power & Utilities (AQN)

Suzhou Ribo Seeks Venous Thromboembolism Drug Trial in Europe

MT Newswires Live

Press Release: Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Suzhou Ribo Advances Vortosiran With EMA Filing for Phase 2b VTE Trial

Emera (EMA) Receives a Hold from Barclays

Press Release: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Emera Q1 Adjusted Earnings, Revenue Rise

MT Newswires Live

Emera reports Q1 adjusted EPS $1.37 vs. $1.28 last year

Earnings Flash (EMA) Emera Posts Q1 Adjusted EPS CA$1.37, vs. FactSet Est of CA$1.20

MT Newswires Live

Emera Q1 Adj. EPS $1.00 Beats $0.89 Estimate

Benzinga Earnings

Press Release: Emera Reports 2026 First Quarter Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/EMA/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":49.19,"timestamp":1789156800000,"preClose":49.48,"halted":0,"volume":322535,"hourTrading":{"tag":"盘后","latestPrice":49.19,"preClose":49.19,"latestTime":"19:30 EDT","volume":114920,"amount":5650342.26916,"timestamp":1789169408200,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.005860953920776055,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Market Closed","change":-0.29,"latestTime":"09-11 16:00:00 EDT","open":49.49,"high":49.58,"low":49.03,"amount":15887316.78782,"amplitude":0.011116,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":49.48,"dividendRate":0.04287,"postHourTrading":{"tag":"盘后","latestPrice":49.19,"preClose":49.19,"latestTime":"19:30 EDT","volume":114920,"amount":5650342.26916,"timestamp":1789169408200,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6549588303916867,"impliedVol":0.3093,"impliedVolPercentile":0.8884},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":0.6549588303916867,"shares":305783111,"dividePrice":2.108663,"high":49.58,"amplitude":0.011116,"preClose":49.48,"low":49.03,"week52Low":45.77,"pbRate":"1.61","psRate":"2.33","week52High":55.49,"institutionHeld":0,"latestPrice":49.19,"eps":2.229761,"divideRate":0.042868,"volume":322535,"delay":0,"ttmEps":2.229761,"open":49.49,"prevYearClose":49.24,"prevWeekClose":50.35,"prevMonthClose":50.09,"prevQuarterClose":53.02,"fiveDayClose":50.3,"twentyDayClose":51.34,"sixtyDayClose":52.55,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-09-11","current":22.06066,"percent":0.489097,"low":16.637027,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"high":22.07626,"avg":19.825742,"sd":1.478156,"marketCap":15223834714.33},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26},{"date":"2026-08-28","current":20.499692,"twenty":17.645049,"median":20.225489,"eighty":21.044992,"marketCap":15379168560.24},{"date":"2026-09-04","current":20.473108,"twenty":17.659944,"median":20.257815,"eighty":21.043803,"marketCap":15442660903.12},{"date":"2026-09-11","current":20.227938,"twenty":17.708223,"median":20.275847,"eighty":21.041773,"marketCap":15223834714.33}],"updateTime":1789251630413},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635746529","title":"Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635746529","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635746529?lang=en_us&edition=fundamental","pubTime":"2026-05-14 22:47","pubTimestamp":1778770020,"startTime":"0","endTime":"0","summary":"-- Updated positive data from iadademstat in 1L AML unfit patients to be. presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract. -- Ongoing broad expansion of iadademstat clinical development across. PORTICO-2 Phase III trial with vafidemstat in aggression in BPD. -- Strong cash position at the quarter ended March 2026: $25.4 million. \"The iadademstat development platform continues to expand, reinforcing its potential as a high-value hematology and oncology asset,\" Dr. Buesa continued. \"Enrollment is advancing across multiple investigator-sponsored studies at leading U.S. cancer centers and National Cancer Institute-sponsored trials in hematologic malignancies and solid tumors. At the same time, em","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","CR","BK4144","PTA","BK4585","ET","BK4561","ORR","SCD","BK4590","BK4202","BK4581","BK4161","BK4081","EMA","NCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635899437","title":"Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635899437","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635899437?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:11","pubTimestamp":1778670660,"startTime":"0","endTime":"0","summary":"CARDAMYST (etripamil) nasal spray launch for PSVT isgaining traction; breadth of unique prescribers supportspotential future adoptionExpress Scripts national formulary coverage secured as company make","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293867/0/en/Milestone-Pharmaceuticals-Announces-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AV","BK4585","ECG","LU1559883803.SGD","LU0566484027.USD","EMA","BK4129","MAA","BK4588","BK4081","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635882276","title":"EMA Partners Appoints Alicia Yi as Group Executive Advisor, Strengthening Executive Search & Leadership Advisory Capabilities Across APAC","url":"https://stock-news.laohu8.com/highlight/detail?id=2635882276","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635882276?lang=en_us&edition=fundamental","pubTime":"2026-05-13 12:01","pubTimestamp":1778644860,"startTime":"0","endTime":"0","summary":"SINGAPORE, May 13, 2026 /PRNewswire/ -- Global executive search and leadership advisory firm EMA Partners today announced that former Korn Ferry Vice Chair Alicia Yi has joined the firm as Group Executive Advisor, based in Singapore.Her appointment comes as organisations across Asia-Pacific navigate increasing complexity in leadership — from CEO succession and board composition to accelerating digital and AI-driven transformation. Across the region, companies are placing greater emphasis on senior-led, advisory-driven engagement to support critical leadership decisions, particularly as Singapore continues to strengthen its role as a regional hub for leadership decision-making across Asia-Pacific and ASEAN.Alicia began her career in human capital consulting at Towers Perrin in Singapore and Chicago, before taking on an international HR leadership role at Swiss Bank Corporation in Zurich. Her cross-border and multidisciplinary background has made her a sought-after advisor on CEO success","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ema-partners-appoints-alicia-yi-as-group-executive-advisor-strengthening-executive-search--leadership-advisory-capabilities-across-apac-302770361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APAC","BK4105","BK4588","EMA","IWF","BK4581","BK4585","BK4081","AESC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635280247","title":"Press Release: Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2635280247","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635280247?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:08","pubTimestamp":1778616480,"startTime":"0","endTime":"0","summary":"- Duchenne : First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program's global development -. - Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 -. - Friedreich's Ataxia : Second participant dosed in the Phase 1b FALCON clinical trial; SGT-212 has been well tolerated with no serious adverse events observed -. - CPVT : Company anticipates dosing the first participant in the Phase 1b ARTEMIS clinical trial evaluating SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia  in H2 2026 -. \"In parallel, we are working closely with the UK Medic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4539","PIP","BK4139","BK4130","EC","BK4535","BK4081","TM","FA","BK4099","BK4555","BK4201","EMA","BK4585","BK4588","SLDB","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634521637","title":"BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1","url":"https://stock-news.laohu8.com/highlight/detail?id=2634521637","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634521637?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:30","pubTimestamp":1778585400,"startTime":"0","endTime":"0","summary":"- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-sp","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292712/0/en/BridgeBio-Submits-NDA-to-FDA-for-Encaleret-for-Individuals-Living-with-ADH1.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4081","LABU","BK4215","MAA","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232265","title":"Press Release: LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232265","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232265?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:05","pubTimestamp":1778529900,"startTime":"0","endTime":"0","summary":"Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ product sales. Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch through Q1 2026. Together with Sarah Jessica Parker, launched the DTC campaign in Q1 2026. Management to host conference call today, May 11, 2026, at 4:30 p.m. EDT. SAN DIEGO, May 11, 2026  -- LENZ Therapeutics, Inc. , a pharmaceutical company focused on the commercialization of VIZZ  1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today reported financial results for the first quarter ended March 31, 2026 and recent corporate highlights.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4081","BK4585","LENZ","BK4588","BK4215","MAA","BK4007","BK4539","BK4139","EMA","R","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634231804","title":"Emera price target raised to C$74 from C$73 at CIBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2634231804","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634231804?lang=en_us&edition=fundamental","pubTime":"2026-05-12 02:06","pubTimestamp":1778522774,"startTime":"0","endTime":"0","summary":"CIBC raised the firm’s price target on Emera (EMA) to C$74 from C$73 and keeps a Neutral rating on the shares. Published first on TheFly – the ulti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-price-target-raised-to-c74-from-c73-at-cibc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-price-target-raised-to-c74-from-c73-at-cibc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634605236","title":"Press Release: GENFIT Annual Combined General Meeting of June 15, 2026 -- Availability of Preparatory Documents","url":"https://stock-news.laohu8.com/highlight/detail?id=2634605236","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634605236?lang=en_us&edition=fundamental","pubTime":"2026-05-12 01:00","pubTimestamp":1778518800,"startTime":"0","endTime":"0","summary":"Lille , Cambridge , Zurich , May 11, 2026 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the May 11, 2026 French legal announcements bulletin ndeg56  the notice of the Combined Shareholders Meeting, which will be held on June 15, 2026, at 10:00 am , at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.All documentation regarding this Combined Shareholders' Meeting will be available to shareholders in accordance with existing regulations on the Company's website, in the Financials section under the Combined Shareholders Meeting tab .The Combined Shareholders' Meeting will be broadcasted live and will be available on the Company's website in the same section. A recording of the Combined Shareholders' Meeting will be available on the Company's website within the time frame specified by regulatio","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USA","BK4081","HE","BK4099","BK4588","AD","CET","BK4022","BK4555","EMA","PBC","CCA","BK4132","BK4585","03160","BK4232","BK4604","TM","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634821492","title":"Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2634821492","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634821492?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:30","pubTimestamp":1778506200,"startTime":"0","endTime":"0","summary":"-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM, further reinforcing its differentiated prof","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3291995/0/en/Acoramidis-Continues-to-Demonstrate-Disease-Modifying-Effects-in-ATTR-CM-Reducing-sTTR-Variability-and-Outpatient-Worsening-Heart-Failure.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0187121727.USD","LU1861214812.USD","LU0689626769.HKD","EMA","BK4129","LU1939255532.USD","LU2308191902.HKD","LU2238339852.HKD","ATTR","ACM","LU2360107325.USD","CM","LU1861219969.SGD","BK4207","LU0124676726.USD","LU2298064838.USD","BK4516","LU2244417387.USD","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634285232","title":"Analysts Have Conflicting Sentiments on These Utilities Companies: Emera (EMA), PPL (PPL) and Algonquin Power & Utilities (AQN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634285232","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634285232?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:40","pubTimestamp":1778499650,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Utilities sector with new ratings on Emera (EMA), PPL (PPL) and Algonquin Power & Utilities (AQN). Emer...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-utilities-companies-emera-ema-ppl-ppl-and-algonquin-power-utilities-aqn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-utilities-companies-emera-ema-ppl-ppl-and-algonquin-power-utilities-aqn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","AQN","BK4208","IE00BD4GTT62.SGD","BK4588","LU0787776722.HKD","LU1093756168.USD","BK4585","IE00BN8TJ469.HKD","BK4081","IE00BLSP4452.SGD","IE00BLSP4239.USD","AQNB","LU0208291251.USD","IE00BBT3K403.USD","LU0070302665.USD","IE00BD4GTW91.USD","LU1093756325.SGD","PPL","IE00BD4GTV84.USD","LU0320765489.SGD","LU2449327464.USD","LU0683600562.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634780283","title":"Suzhou Ribo Seeks Venous Thromboembolism Drug Trial in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2634780283","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634780283?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:20","pubTimestamp":1778498424,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for Vortosiran at the European Medicines Agency (EMA), according to a Monday Hong Kong bourse filing.The trial aims to study the drug for the prevention of venous thromboembolism.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06938","BK7129","EMA.AU","BK1161","BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634828842","title":"Press Release: Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2634828842","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634828842?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:00","pubTimestamp":1778497200,"startTime":"0","endTime":"0","summary":"-- Elraglusib oral tablet formulation to drive next-phase clinical. -- FDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer. patients, with focus on metastatic melanoma, NSCLC, colorectal, and. pancreatic cancers with initiation planned for 2H 2026. To support this initiative, the Company recently received Investigational New Drug  clearance from FDA to conduct a Phase 1/2 study designed to demonstrate that a higher overall exposure to elraglusib can be achieved with the oral formulation compared to the IV formulation. The study will evaluate the safety and potential efficacy of the oral formulation as a monotherapy in solid tumor patients, including those with metastatic melanoma, NSCLC, colorectal, and pancreatic cancers, based on evidence of efficacy of the IV formulation in prior clinical studies and machine learning therapeutic target analyses.\"Advancing the elraglusib oral tablet is an important element to the success of our overall development strategy,\" sai","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYQQ9H92.USD","LU2413666426.HKD","LU0347712357.USD","LU1093756325.SGD","IND","LU2413666699.HKD","BK4585","BK4548","BK4567","EMA","IE00BFXG0V08.USD","BK4121","BK4081","BK4218","LABU","LU1721428933.USD","LU2211817866.USD","MTD","BK4139","ACTU","BK4588","IE00B5TLWC47.USD","PK","LU1093756168.USD","BK4181","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634050407","title":"Suzhou Ribo Advances Vortosiran With EMA Filing for Phase 2b VTE Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634050407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634050407?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:12","pubTimestamp":1778494370,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. Class H ( ($HK:6938) ) has provided an update. Suzhou Ribo Life Science has submitted a phase 2b clinical trial ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/suzhou-ribo-advances-vortosiran-with-ema-filing-for-phase-2b-vte-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/suzhou-ribo-advances-vortosiran-with-ema-filing-for-phase-2b-vte-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634840658","title":"Emera (EMA) Receives a Hold from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2634840658","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634840658?lang=en_us&edition=fundamental","pubTime":"2026-05-11 16:00","pubTimestamp":1778486409,"startTime":"0","endTime":"0","summary":"In a report released today, Michael Lonegan from Barclays maintained a Hold rating on Emera, with a price target of $52.00. According to TipRanks, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/emera-ema-receives-a-hold-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/emera-ema-receives-a-hold-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633535974","title":"Press Release: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633535974","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633535974?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:30","pubTimestamp":1778239800,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc.  , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent updates and financial results for the quarter ended March 31, 2026.\"We remain disappointed with the unanticipated outcome of the FLASH2  study,\" stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. \"Despite the fact that HyBryte  demonstrated statistically significant reductions in cutaneous T-cell lymphoma  lesions after 6 weeks treatment in the first FLASH study, a similar signal was not observed with 18 weeks of treatment in this study. Over the coming weeks, we will analyze the data to better determine why the study did not meet expectations. If there is any clarity gained from further analysis of the dataset, especially with respect to specific subsets of patients that may benefit from HyBryte therapy, then w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4588","BK4232","BK4604","BK4081","BK4555","TM","BK4099","BK4139","R","SNGX","PIM","EMA","IDR","BK4585","BK4022","BK4168"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432748","title":"Emera Q1 Adjusted Earnings, Revenue Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432748","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633432748?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:31","pubTimestamp":1778236298,"startTime":"0","endTime":"0","summary":"Emera  reported Q1 adjusted earnings Friday of 1.37 Canadian dollars  per share, up from CA$1.28 a year earlier.Analysts polled by FactSet expected CA$1.20.Revenue for the quarter ended March 31 was CA$2.81 billion, up from CA$2.68 billion a year earlier.Three analysts polled by FactSet expected CA$2.42 billion.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4081","EMA","BK7129","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633843295","title":"Emera reports Q1 adjusted EPS $1.37 vs. $1.28 last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2633843295","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633843295?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:13","pubTimestamp":1778235232,"startTime":"0","endTime":"0","summary":"“Emera (EMA) delivered a solid first quarter, with important regulatory outcomes, disciplined capital deployment and record results at Emera Energy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-reports-q1-adjusted-eps-1-37-vs-1-28-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-reports-q1-adjusted-eps-1-37-vs-1-28-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633543476","title":"Earnings Flash (EMA) Emera Posts Q1 Adjusted EPS CA$1.37, vs. FactSet Est of CA$1.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2633543476","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633543476?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:10","pubTimestamp":1778235035,"startTime":"0","endTime":"0","summary":"Earnings Flash (EMA) Emera Posts Q1 Adjusted EPS CA$1.37, vs. FactSet Est of CA$1.20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA","CA","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633443443","title":"Emera Q1 Adj. EPS $1.00 Beats $0.89 Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633443443","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633443443?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:07","pubTimestamp":1778234873,"startTime":"0","endTime":"0","summary":"Emera (NYSE:EMA) reported quarterly earnings of $1.00 per share which beat the analyst consensus estimate of $0.89 by 12.36 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52402045/emera-q1-adj-eps-1-00-beats-0-89-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633460434","title":"Press Release: Emera Reports 2026 First Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633460434","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633460434?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:06","pubTimestamp":1778234760,"startTime":"0","endTime":"0","summary":"Today, May 8, 2026, Emera Inc.   reported 2026 first quarter financial results .--  Delivered a 7% increase in adjusted earnings per share2 , with. $1.37 in Q1 2026, compared to $1.28 in Q1 2025, and reported EPS of $1.85. --  On track to deliver 2026 adjusted EPS2 growth above our earnings. Q1 2026 reported net income was $562 million, or $1.85 per common share, compared to net income of $583 million, or $1.96 per common share, in Q1 2025.In Q1 2026, the translation impacts of a stronger CAD on USD denominated earnings decreased adjusted net income by $17 million and decreased reported net income by $30 million, compared to the same period in 2025. These impacts include the effect of FX hedges used to mitigate translation risk of USD earnings, which are included in Corporate in the Other segment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}